title: cDNA microarray analysis of pigment epithelium-derived factor-regulated gene expression profile in prostate carcinoma cells.
abstract: OBJECTIVE
  To clarify molecular mechanisms involved in the action of pigment epithelium-derived factor (PEDF) in hormone insensitive prostate cancer cells.
  
  
  METHODS
  Total ribonucleic acid from untreated and PEDF-treated cells was subjected to microarray analysis using BioStar 8464 microarray. Real-time polymerase chain reaction analysis was conducted to confirm the microarray data.
  
  
  RESULTS
  Twenty-seven out of 8464 genes were found altered in both cell lines. Common gene responses altered by PEDF were identified and included genes known to alter cell signaling as well as genes involved in catalytic activity, cell proliferation, angiogenesis and apoptosis. Real-time reverse transcription polymerase chain reaction, in accordance with the microarray analysis, indicated that PEDF treatment caused an upregulation in the mRNA expression level of stanniocalcin 2, brain-specific angiogenesis inhibitor 2 and growth arrest, DNA-damage-inducible, alpha, and downregulation in the messenger ribonucleic acid level of fibroblast growth factor 3, teratocarcinoma-derived growth factor, neuropilin1, and endothelial Per/ARNT/Sim domain protein1, respectively.
  
  
  CONCLUSIONS
  These findings demonstrate that PEDF administration causes significant changes in the gene expression of the prostate, providing insights into the potential role of PEDF in the treatment of prostate cancer.
authors.affiliation: Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
authors.forename: Weiwei
authors.initials: W
authors.lastname: Liu
authors.forename: Zhong
authors.initials: Z
authors.lastname: Wu
authors.forename: Ming
authors.initials: M
authors.lastname: Guan
authors.forename: Yuan
authors.initials: Y
authors.lastname: Lu
mesh_terms: D015153:Blotting, Western; D045744:Cell Line, Tumor / Q000166:cytology / Q000187:drug effects*; D018076:DNA, Complementary / Q000032:analysis* / Q000187:drug effects / Q000235:genetics; D005136:Eye Proteins / Q000378:metabolism / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008297:Male; D046228:Microarray Analysis; D009414:Nerve Growth Factors / Q000378:metabolism / Q000494:pharmacology*; D011336:Probability; D011467:Prostate / Q000166:cytology; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D015843:Serpins / Q000378:metabolism / Q000494:pharmacology*; D000099174:Pigment Epithelium-Derived Factor
chemical_list: D018076:DNA, Complementary; D005136:Eye Proteins; D009414:Nerve Growth Factors; D012333:RNA, Messenger; D015843:Serpins; D000099174:Pigment Epithelium-Derived Factor